stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.65
0.23
+2.44%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Debt to equity
Telix Pharmaceuticals Limited's debt to equity at the end of the quarter to 30 June 2026 was 1.2×, up 0.1× from fiscal 2025 (1.1×). That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 1.1× | 9.36% |
| FY2024 | 1.0× | 797.61% |
| FY2023 | 0.1× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 1.2× | 6.28% |
| Dec 2025 | 1.1× | 14.39% |
| Jun 2025 | 1.0× | (4.69%) |
| Dec 2024 | 1.0× | 1,930.28% |
| 2 more quarters | Free account |
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| CELC Celcuity, Inc. compare | −58.9× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| IDYA IDEAYA Biosciences, Inc. compare | 0.0× |
| ELVN Enliven Therapeutics, Inc. compare | 0.0× |
| DNLI Denali Therapeutics Inc. compare | 0.0× |
| DYN Dyne Therapeutics, Inc. compare | 0.3× |
| VKTX Viking Therapeutics, Inc. compare | 0.4× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 0.7× |
| TLX Telix Pharmaceuticals Limited | 1.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)